Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Reference Dentifrice (1100 ppm fluoride as SnF2) is a fluoride-containing toothpaste formulation used as a comparative control in clinical studies sponsored by Haleon, specifically for evaluating treatments for tooth erosion and enamel remineralization. This reference product contains 1100 parts per million (ppm) fluoride delivered in the form of stannous fluoride (SnF2). Stannous fluoride is a multi-benefit oral care agent recognized for its ability to provide anti-caries protection, reduce gingivitis, and alleviate dentin hypersensitivity. In the context of dental erosion, stannous ions deposit on the enamel surface to form a protective, acid-resistant barrier (stannous-rich pellicle), while fluoride ions promote the remineralization of acid-softened enamel by facilitating the formation of fluorapatite. In clinical trials, it serves as a benchmark to measure the efficacy of experimental formulations in protecting against acid challenges and aiding enamel recovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Reference Dentifrice (1100 ppm fluoride as SnF2).